CA2950088A1 - Heterobifunctional compounds having a triazole linker and e and/or p selectin binding affinity - Google Patents

Heterobifunctional compounds having a triazole linker and e and/or p selectin binding affinity Download PDF

Info

Publication number
CA2950088A1
CA2950088A1 CA2950088A CA2950088A CA2950088A1 CA 2950088 A1 CA2950088 A1 CA 2950088A1 CA 2950088 A CA2950088 A CA 2950088A CA 2950088 A CA2950088 A CA 2950088A CA 2950088 A1 CA2950088 A1 CA 2950088A1
Authority
CA
Canada
Prior art keywords
chosen
groups
compound
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2950088A
Other languages
English (en)
French (fr)
Inventor
Beat Ernst
Beatrice Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescent Biopharma Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of CA2950088A1 publication Critical patent/CA2950088A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2950088A 2015-12-02 2016-11-30 Heterobifunctional compounds having a triazole linker and e and/or p selectin binding affinity Abandoned CA2950088A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562262155P 2015-12-02 2015-12-02
US62/262,155 2015-12-02

Publications (1)

Publication Number Publication Date
CA2950088A1 true CA2950088A1 (en) 2017-06-02

Family

ID=57681725

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2950088A Abandoned CA2950088A1 (en) 2015-12-02 2016-11-30 Heterobifunctional compounds having a triazole linker and e and/or p selectin binding affinity

Country Status (5)

Country Link
US (1) US20200171005A9 (OSRAM)
EP (1) EP3383882A1 (OSRAM)
JP (1) JP2019501130A (OSRAM)
CA (1) CA2950088A1 (OSRAM)
WO (1) WO2017095904A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
CA3037850A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CA3085356A1 (en) * 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2020219419A1 (en) * 2019-04-24 2020-10-29 Glycomimetics, Inc. Multimeric pan–selectin antagonists
US20220289784A1 (en) * 2019-08-20 2022-09-15 Glycomimetics, Inc. Process for preparing an e-selectin inhibitor intermediate
WO2021195465A1 (en) 2020-03-27 2021-09-30 Magnani John L Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin
CN115666584A (zh) 2020-05-31 2023-01-31 糖模拟物有限公司 用于减少癌细胞负荷和保护正常血细胞生成的化合物和方法
JP2023529485A (ja) 2020-06-14 2023-07-10 グリコミメティクス， インコーポレイテッド Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法
WO2023014690A1 (en) 2021-08-03 2023-02-09 Glycomimetics, Inc. Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511174A1 (en) * 2002-12-20 2004-07-15 Glycomimetics, Inc. Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection
LT2264043T (lt) * 2005-09-02 2017-12-11 Glycomimetics, Inc. Heterobifunkciniai pan-selektino inhibitoriai
WO2009126556A1 (en) * 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
WO2012037034A1 (en) * 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists

Also Published As

Publication number Publication date
WO2017095904A1 (en) 2017-06-08
US20180369205A1 (en) 2018-12-27
EP3383882A1 (en) 2018-10-10
US20200171005A9 (en) 2020-06-04
JP2019501130A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
CA2950088A1 (en) Heterobifunctional compounds having a triazole linker and e and/or p selectin binding affinity
AU2023204344A1 (en) Highly potent multimeric E-selectin antagonists
AU2018395417B2 (en) Heterobifunctional inhibitors of E-selectin and galectin-3
CA3062649A1 (en) Compounds for the treatment of systemic insulin resistance disorders and the use thereof
EP3166956B1 (en) Novel hybrid galactoside inhibitor of galectins
CA3054605A1 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
PT1934236E (pt) Inibidores de pan-selectina heterobifuncionais
CA3062648A1 (en) Compounds for the prevention and treatment of diseases and the use thereof
US20170296566A9 (en) Methods and compositions for treating and/or preventing mucositis
US20120028915A1 (en) 6"-amino-6"-deoxygalactosylceramides
JP2016501840A (ja) Ｅ−セレクチンアンタゴニスト化合物および使用方法
EP1685145A2 (en) Glycomimetic antagonists for both e- and p-selectins
US20230079833A1 (en) Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
Manta et al. Unsaturated fluoro-ketopyranosyl nucleosides: Synthesis and biological evaluation of 3-fluoro-4-keto-β-D-glucopyranosyl derivatives of N4-benzoyl cytosine and N6-benzoyl adenine
WO2020219419A1 (en) Multimeric pan–selectin antagonists
EP2170912B1 (en) New phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same
Vasan et al. Agonistic and antagonistic properties of a Rhizobium sin-1 lipid A modified by an ether-linked lipid
EP4143200A1 (en) Cd33 ligands suitable for incorporation into carriers
WO2021222767A1 (en) Cd33 ligands suitable for incorporation into carriers
WO2023060021A1 (en) Polar cd33 ligands suitable for incorporation into carriers
JP2022542288A (ja) 再構成骨髄枯渇宿主の生存を高めるためのｅ－セレクチンアンタゴニストの使用
US20230091472A1 (en) Galectin-3 inhibiting c-glycoside ketones, ethers, and alcohols
CA2452530C (en) Novel immunosuppressive agent
WO2022250976A1 (en) Galectin-3 inhibiting c-glycoside oximes

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230221

FZDE Discontinued

Effective date: 20230221